Effect of Dunhuang Pingweiwan and Its Decomposed Recipes on Tumor Inhibition and PI3K/Akt/mTOR Pathway in SCG-7901 Gastric Cancer Mice

Ya-li SHE; Xiao-wen ZHAO; Jun-jie LI; Juan-juan DONG; Yong-qi LIU; Xi-ping LIU; Chang-tian LI; Ya-ling LI

doi:10.13422/j.cnki.syfjx.20202229

您当前的位置：

首页 >

文章列表页 >

Effect of Dunhuang Pingweiwan and Its Decomposed Recipes on Tumor Inhibition and PI3K/Akt/mTOR Pathway in SCG-7901 Gastric Cancer Mice

Pharmacology | 更新时间：2021-02-09

- Effect of Dunhuang Pingweiwan and Its Decomposed Recipes on Tumor Inhibition and PI3K/Akt/mTOR Pathway in SCG-7901 Gastric Cancer Mice
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 5, Pages: 70-76(2021)
- 作者机构：
  
  甘肃中医药大学敦煌医学与转化教育部重点实验室，甘肃省高校重大疾病分子医学与中医药防治研究省级重点实验室，兰州 730000
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20202229
  CLC： R22;R242;R2-031;R285.5
- Published：05 March 2021，
  
  Published Online：03 September 2020，
  
  Received：06 July 2020，
- 稿件说明：
扫描看全文
舍雅莉,赵晓文,李俊杰等.敦煌平胃丸及其拆方对SCG-7901胃癌荷瘤小鼠的抑瘤作用及对PI3K/Akt/mTOR信号通路的影响[J].中国实验方剂学杂志,2021,27(05):70-76.

SHE Ya-li,ZHAO Xiao-wen,LI Jun-jie,et al.Effect of Dunhuang Pingweiwan and Its Decomposed Recipes on Tumor Inhibition and PI3K/Akt/mTOR Pathway in SCG-7901 Gastric Cancer Mice[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(05):70-76.
舍雅莉,赵晓文,李俊杰等.敦煌平胃丸及其拆方对SCG-7901胃癌荷瘤小鼠的抑瘤作用及对PI3K/Akt/mTOR信号通路的影响[J].中国实验方剂学杂志,2021,27(05):70-76. DOI： 10.13422/j.cnki.syfjx.20202229.

SHE Ya-li,ZHAO Xiao-wen,LI Jun-jie,et al.Effect of Dunhuang Pingweiwan and Its Decomposed Recipes on Tumor Inhibition and PI3K/Akt/mTOR Pathway in SCG-7901 Gastric Cancer Mice[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(05):70-76. DOI： 10.13422/j.cnki.syfjx.20202229.

摘要

目的

研究敦煌平胃丸及其拆方对胃癌荷瘤小鼠的抑瘤作用，并从磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（Akt）/哺乳动物雷帕霉素靶蛋白（mTOR）信号通路研究敦煌平胃丸及其拆方可能的作用机制。

方法

建立SCG-7901胃癌皮下荷瘤小鼠模型，随机分为模型组，敦煌平胃丸组（14.04 g·kg

-1

·d

-1

），活血解毒组（6.50 g·kg

-1

·d

-1

），温中散寒组（3.64 g·kg

-1

·d

-1

）和顺铂组（2 mg·kg

-1

·d

-1

），每组8只。接种第8天开始给药，连续10 d，隔日小鼠称体质量并观察一般情况；末次给药后次日处死小鼠，剥取肿瘤称质量，计算抑瘤率；苏木素-伊红（HE）染色观察肿瘤组织病理学变化，实时荧光定量聚合酶链式反应（Real-time PCR）和免疫组化法（IHC）分别检测肿瘤组织中PI3K，Akt，mTOR mRNA和蛋白表达情况。

结果

接种第10天开始，顺铂组小鼠一般情况较差，体质量下降，模型、敦煌平胃丸、活血解毒和温中散寒组小鼠一般情况尚可，体质量增长，组间差异无统计学意义；敦煌平胃丸、活血解毒、温中散寒和顺铂组抑瘤率分别为30.74%，24.80%，4.19%和63.84%，除温中散寒组外，其余给药组瘤质量均较模型组显著降低（

0.01），其中敦煌平胃丸与活血解毒组间差异无统计学意义；敦煌平胃丸和活血解毒组能明显降低肿瘤细胞密度，引起肿瘤细胞坏死；与模型组比较，敦煌平胃丸、活血解毒和顺铂组PI3K，Akt，mTOR mRNA和蛋白表达均明显下降（

0.05，

0.01），其中敦煌平胃丸与活血解毒组差异无统计学意义。

结论

敦煌平胃丸及其拆方（活血解毒方）对SCG-7901胃癌荷瘤小鼠具有一定的抑瘤作用，其机制可能与下调PI3K/Akt/mTOR信号通路关键分子表达有关。

Abstract

Objective

To investigate the antitumor effect and the mechanism of Dunhuang Pingweiwan and its decomposed recipes based on phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt）/mammalian target of rapamycin （mTOR） signaling pathway in SCG-7901 gastric cancer-mice.

Method

The subcutaneous tumor bearing model of SCG-7901 gastric cancer in mice was established， and the the mice were randomized into model group， Dunhuang Pingweiwan group （14.04 g·kg

-1

·d

-1

）， Huoxue Jiedu group （6.50 g·kg

-1

·d

-1

）， Wenzhong Sanhan group （3.64 g·kg

-1

·d

-1

） and cisplatin group （2 mg·kg

-1

·d

-1

）， with 8 mice in each group. From the 8

day of inoculation， the mice were administered for 10 consecutive days. The mice were weighed and the general conditions were observed every other day. On the next day of the last administration， the mice were sacrificed， and the tumor was removed and weighed to calculate the anti-tumor rate. The histopathological changes were observed by hematoxylin-eosin （HE） staining， and the mRNA and protein expressions of PI3K， Akt， and mTOR in tumor tissues were detected by real-time polymerase chain reaction（Real-time PCR） and immunohistochemistry （IHC）， respectively.

Result

From the 10

day of inoculation， the mice in cisplatin group were generally in poor condition and their body mass decreased. The mice in model group， Dunhuang Pingweiwan group， Huoxue Jiedu group and Wenzhong Sanhan group were generally fair， and their body mass increased without significant difference among groups. The tumor inhibition rates of Dunhuang Pingweiwan， Huoxue Jiedu， Wenzhong Sanhan and cisplatin groups were 30.74%， 24.80%， 4.19% and 63.84%， respectively. Except for Wenzhong Sanhan group， tumor weight of the other treatment groups was significantly lower than that of the model group （

0.01）， and there was no significant difference between the Dunhuang Pingweiwan and Huoxue Jiedu group. Dunhuang Pingweiwan and Huoxue Jiedu group could significantly reduce tumor cell density and cause tumor cell necrosis. Compared with the model group， the expressions of PI3K， Akt， and mTOR mRNA and protein in the Dunhuang Pingweiwan， Huoxue Jiedu and cisplatin groups significantly decreased （

0.05，

0.01）， and there was no significant difference between the Dunhuang Pingweiwan group and Huoxue Jiedu group.

Conclusion

Dunhuang Pingweiwan and its decomposed recipes （Huoxue Jiedu） have a certain anti-tumor effect on the SCG-7901 gastric cancer-mice， and the mechanism may be related to the down-regulation of key molecules in the PI3K/Akt/mTOR signaling pathway.

关键词

敦煌平胃丸胃癌磷脂酰肌醇3-激酶（PI3K）蛋白激酶B（Akt）哺乳动物雷帕霉素靶蛋白（mTOR）

Keywords

Dunhuang Pingweiwangastric cancerphosphatidylinositol 3-kinase （PI3K）protein kinase B （Akt）mammalian target of rapamycin （mTOR）

references

裴晓华，彭艳梅.中医药治疗恶性肿瘤70年［J］.中国肿瘤外科杂志，2019，11（5）：305-308.

袁选举，邓守恒.中医药在治疗恶性肿瘤中的研究进展［J］.时珍国医国药，2019，30（9）：2232-2234.

贺习婷，杜井富，刘咏菲，等.常见恶性肿瘤的中医治疗原则浅析［J］.中西医结合心血管病电子杂志，2020，8（4）：39，55．

王春宇，王睿林，艾永强，等.活血化瘀方对小鼠Hepa1-6肝癌转移和生长的作用及机制初探［J］.中药药理与临床，2019，35（6）：110-116.

李怡帆，李娟，卢雯平.益气活血解毒方对小鼠卵巢癌ID-8细胞株增殖及血管生成过程的影响［J］.中国实验方剂学杂志，2018，24（4）：154-159.

刘喜平，李沛清，辛宝，等.敦煌遗书《亡名氏脉经》佚方考［J］.中国中医基础医学杂志，2012，18（4）：362-364.

刘喜平.敦煌医方的理论与实践［M］.北京：中医古籍出版社，2012：75.

付航，刘喜平，李沛清，等.敦煌平胃丸治疗慢性萎缩性胃炎癌前病变48例［J］.中医研究，2015，28（1）：20-22.

舍雅莉，闫德祺，刘永琦，等.当归贝母苦参丸对顺铂化疗H22荷瘤小鼠肿瘤及肝脏、肾脏和胸腺组织病理形态的影响［J］.中国中医药信息杂志，2014，21（5）：56-60.

祝小惠，钟相根，程发峰，等.谈“法依病机、拆方依法”的经方拆方研究思路及其优势［J］.辽宁中医杂志，2011，38（5）：857-859.

蒋锐沅，莫春梅，满婷婷，等.西黄丸对炎症微环境下肺癌A549荷瘤小鼠NLRP3炎症小体及其产物和肿瘤增殖的影响［J］.中国实验方剂学杂志，2020，26（17）：20-28.

TATEBAYASHI D， HIMORI K， YAMADA R，et al. High-intensity eccentric training ameliorates muscle wasting in colon 26 tumor-bearing mice［J］. PLoS One，2018，13（6）： e0199050.

步宏，李一雷.病理学［M］.9版.北京：人民卫生出版社，2018：95.

BRAGLIA L， ZAVATTI M， VINCETI M，et al. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer： still a potential druggable target？［J］. Biochim Biophys Acta Mol Cell Res，2020，1867（9）：118731.

MA S S，LIU T F，XU L，et al.Histone deacetylases inhibitor MS‐275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway［J］. J Cell Physiol，2019，234（12）：22400-22410.

GOETZE O T，AL-BATRAN S E，CHEVALLAY M，et al. Multimodal treatment in locally advanced gastric cancer［J］.Updates Surg，2018，70（2）：173-179.

BALAKRISHNAN K， PELUSO M， FU M， et al. The phosphoinositide-3-kinase（PI3K）-delta and gamma inhibitor，IPI-145 （Duvelisib），overcomes signals from the PI3K/ AKT/ S6 pathway and promotes apoptosis in CLL［J］. Leukemia，2015，29（9）：1811-1822.

ZHENG T， YANG X Y，WU D，et al. Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK/PI3K/Akt/GSK3β pathway［J］. Br J Pharmacol， 2015， 172（13）：3284-3301. ［责任编辑张丰丰］

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Wutou Chishizhi Wan Regulates Autophagy and PI3K/Akt/GSK-3β Signaling Pathway in Rats with Myocardial Ischemia-reperfusion Injury

Effect of Licoflavone A on Proliferation and Glycolysis of Gastric Cancer Cells Under Hypoxic Conditions

Traditional Chinese Medicine Treats Ischemic Stroke by Regulating mTOR Signaling Pathway： A Review

Mechanism on Banxia Xiexintang Inducing Ferroptosis in Gastric Cancer Cells Based on Nrf2/GPX4 Signaling Pathway

Traditional Chinese Medicine Targets mTOR Signaling Pathway for Treatment of Diabetic Kidney Disease： A Review

Related Author

Yu-xue XIAO

Xiao-mei SHI

Lu-lu XIE

Xin-he WANG

Song WANG

Zhao-peng ZHANG

Chun-yu LIAN

Jun-peng GUO

Related Institution

Changchun University of Chinese Medicine

Provincial Key Laboratory of Molecular Medicine and Traditional Chinese Medicine Prevention and Treatment in Gansu Colleges and Universities；Key Laboratory of Dunhuang Medicine， Ministry of Education， Basic Medical College， Gansu University of Chinese Medicine

The Second Affiliated Hospital of Shandong University of TCM

Shandong University of Traditional Chinese Medicine(TCM)

School of Rehabilitation， Shandong University of TCM

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰